Relating to controlled substance schedules and to clean-up errors identified in code sections
SB 858 is a technical update to West Virginia’s controlled substances schedules in Chapter 60A. The bill amends and reenacts multiple schedule provisions to correct drafting and cross-reference errors, while also updating and reorganizing the lists of controlled substances in Schedules I through V. The text includes extensive revisions to the enumerated substances in each schedule, including opioids, hallucinogens, synthetic cannabinoids, stimulants, depressants, anabolic steroids, and other listed drugs, as well as temporary emergency-scheduled substances and immediate precursors.
Although the bill is framed as a “clean-up” measure, it also reflects current controlled-substance enforcement policy by clarifying which compounds are included in each schedule and by preserving specific exceptions, such as certain FDA-approved products and lawful medical or research uses. It also expressly maintains that fentanyl and carfentanil remain Schedule II substances and that some tetrahydrocannabinol-related provisions do not apply to products lawfully manufactured or possessed under other state law provisions. Overall, the bill updates the state’s drug scheduling framework to align statutory language with current substance names, analogs, and chemical classifications.
The bill would amend West Virginia Code §§60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, and 60A-2-212, affecting the state’s controlled substance schedules and related precursor provisions. Its practical impact is to revise the legal classification of numerous substances, including synthetic opioids, cannabinoids, cathinones, benzodiazepines, stimulants, and depressants, and to correct errors in the existing code text. This affects law enforcement, prosecutors, courts, pharmacists, manufacturers, researchers, and anyone handling substances regulated under West Virginia’s controlled substances laws.
The available context suggests generally neutral or procedural sentiment. The bill is presented as a technical housekeeping measure rather than a major policy shift, and the note states that its purpose is to clean up errors identified in the code sections. No committee transcript or vote record is provided, so there is no evidence of recorded opposition or support beyond the bill’s introductory framing.
The main potential points of contention are the breadth and complexity of the scheduling updates, especially the inclusion of many synthetic drugs, fentanyl analogs, cannabinoids, and emerging substances. Stakeholders concerned with criminal enforcement may support the broader and clearer scheduling language, while medical, research, or regulated industry stakeholders may focus on the scope of exceptions and whether the bill could unintentionally capture lawful products or research compounds. The bill’s explicit carve-outs for FDA-approved products and lawful cannabis-related products appear intended to limit such concerns, but no recorded debate is available to show whether those issues were disputed.